While San Diego remains a top biotech hub behind Boston and San Francisco, the city—which hosts this week’s BIO International Convention—has seen employment drop amid economic headwinds.
Anti-obesity drugs have revolutionized the market in the last few years, and have been identified as the emerging industry trend likely to have the greatest impact on the biopharmaceutical industry in the next 12 months, according to GlobalData.
The companies announced today that their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patients with a deadly form of skin cancer.
Edwards Lifesciences on Monday said it has agreed to sell its critical care products unit to Becton Dickinson in an all-cash deal valued at $4.2 billion to sharpen focus on its heart devices business.
Recent M&A activity indicates a potential resurgence in the appetites of larger companies for psychiatric drug development, but experts say the space may not offer a sufficient risk-reward proposition for R&D.
The FDA reviewers said since the difference between JN.1 and newer subvariants such as KP.2 subvariants is not much, it is possible that vaccines developed against JN.1 may adequately protect against KP.2.